RxDoctor Payments Data

Christopher Frick, PA

Medical · Lima, OHNPI 1700010014

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $35,418 of the $46,332 with a category attached, or 76.4%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 94.1% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2023 at $21,016 and has fallen 96.1% since, to $819 in 2025. Among medical clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$46,332in general payments, 2019–2025

Across 213 payments — averaging $217.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$44K
  • AstraZeneca$998
  • Abiomed$240
  • Novartis$218
  • Amgen$215
  • Boston Scientific$158
  • plus $906 from 17 others

What the payments were for

  • Speaking & faculty fees$35,41876%
  • Travel & lodging$6,61514%
  • Food & beverage$4,1909%
  • Education$1090%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,332 in reported general payments places this provider in the 95th percentile of 547 medical providers in Ohio.

See all medical providers in Ohio

Medicare billing

Part B allowed, 2024
$7,435
Medicare patients
69
Services billed
96

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrilintaTicagrelor61$26,174
EliquisApixaban19$12,254
FarxigaDapagliflozin Propanediol11$7,980
Prasugrel Hcl35$3,989
Ranolazine ErRanolazine23$2,563
ClopidogrelClopidogrel Bisulfate113$535
Metoprolol Succinate58$437
Atorvastatin Calcium96$431
Isosorbide Mononitrate ErIsosorbide Mononitrate83$349
Hydralazine Hcl19$280
Carvedilol44$150
Spironolactone28$129
Losartan Potassium31$125
Nitroglycerin14$103
Rosuvastatin Calcium30$98

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta, Farxiga$998$34,15472 claims
PfizerEliquis$40$12,25419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 547 medical providers in Ohio.

Other medical in Lima

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →